SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

Key Points

• SOPHiA GENETICS experienced a 45.4% decrease in short interest in September, bringing the total to 23,700 shares sold short.
• The company reported $0.33 earnings per share for the last quarter, exceeding estimates of ($0.25), with a negative net margin of 40.99%.
• Institutional investors and hedge funds currently hold 31.59% of SOPHiA GENETICS stock, indicating growing interest from major financial players.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 23,700 shares, a decrease of 45.4% from the August 31st total of 43,400 shares. Based on an average trading volume of 60,600 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.1% of the company's stock are sold short. Currently, 0.1% of the company's stock are sold short. Based on an average trading volume of 60,600 shares, the days-to-cover ratio is currently 0.4 days.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH traded down $0.07 during trading hours on Friday, hitting $4.40. The company had a trading volume of 73,263 shares, compared to its average volume of 83,708. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.21 and a current ratio of 3.39. SOPHiA GENETICS has a 1-year low of $2.58 and a 1-year high of $4.92. The company has a market cap of $297.35 million, a PE ratio of -10.00 and a beta of 1.10. The business has a 50 day moving average of $3.48 and a 200-day moving average of $3.23.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.58. SOPHiA GENETICS had a negative net margin of 40.99% and a negative return on equity of 30.69%. The business had revenue of $18.32 million during the quarter, compared to the consensus estimate of $17.49 million. SOPHiA GENETICS has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that SOPHiA GENETICS will post -0.96 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. boosted its stake in shares of SOPHiA GENETICS by 89.0% during the first quarter. Federated Hermes Inc. now owns 189,000 shares of the company's stock worth $627,000 after buying an additional 89,000 shares during the period. Silverberg Bernstein Capital Management LLC lifted its position in SOPHiA GENETICS by 31.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 45,715 shares of the company's stock valued at $142,000 after purchasing an additional 11,040 shares during the period. Bank Pictet & Cie Europe AG lifted its position in SOPHiA GENETICS by 14.4% in the first quarter. Bank Pictet & Cie Europe AG now owns 255,200 shares of the company's stock valued at $847,000 after purchasing an additional 32,200 shares during the period. Ridgewood Investments LLC lifted its position in SOPHiA GENETICS by 1,930.5% in the first quarter. Ridgewood Investments LLC now owns 40,610 shares of the company's stock valued at $135,000 after purchasing an additional 38,610 shares during the period. Finally, Akre Capital Management LLC lifted its position in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the period. Institutional investors and hedge funds own 31.59% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Saturday, September 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of "Hold" and a consensus price target of $8.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.